Session

PP 05 IBD (Posters)

HEALTHCARE RESOURCE UTILIZATION AND TREATMENT USAGE AMONG FLARING AND NON-FLARING PATIENTS WITH ULCERATIVE COLITIS – A REAL-WORLD GLOBAL STUDY
HEALTHCARE RESOURCE UTILIZATION AND TREATMENT USAGE AMONG FLARING AND NON-FLARING PATIENTS WITH ULCERATIVE COLITIS – A REAL-WORLD GLOBAL STUDY

PP 05 IBD (Posters)  et al.

THE EFFECTS OF QINGCHANG WENZHONG DECOCTION ON TISSUE-RESIDENT MEMORY CD4+T CELLS IN MICE WITH ULCERATIVE COLITIS
THE EFFECTS OF QINGCHANG WENZHONG DECOCTION ON TISSUE-RESIDENT MEMORY CD4+T CELLS IN MICE WITH ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

APEX SCORE PROSPECTIVE VALIDATION: AN EXCELLENT PREDICTOR OF FLARES IN SMALL BOWEL’S CROHN’S DISEASE AFTER MUCOSAL HEALING
APEX SCORE PROSPECTIVE VALIDATION: AN EXCELLENT PREDICTOR OF FLARES IN SMALL BOWEL’S CROHN’S DISEASE AFTER MUCOSAL HEALING

PP 05 IBD (Posters)  et al.

ANTI-TNF AGENTS AND VEDOLIZUMAB HAVE SIMILAR SAFETY AS FIRST-LINE BIOLOGIC TREATMENT OF ELDERLY PATIENTS WITH ULCERATIVE COLITIS
ANTI-TNF AGENTS AND VEDOLIZUMAB HAVE SIMILAR SAFETY AS FIRST-LINE BIOLOGIC TREATMENT OF ELDERLY PATIENTS WITH ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

PREVALENCE OF SURGERY IN PATIENTS WITH CROHN’S DISEASE IN AUSTRIA – A NATIONWIDE RETROSPECTIVE STUDY FROM 2011 THROUGH 2019
PREVALENCE OF SURGERY IN PATIENTS WITH CROHN’S DISEASE IN AUSTRIA – A NATIONWIDE RETROSPECTIVE STUDY FROM 2011 THROUGH 2019

PP 05 IBD (Posters)  et al.

IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH
IDENTIFICATION OF URINE AND SERUM DIAGNOSTIC BIOMARKERS OF INFLAMMATORY BOWEL DISEASE USING A PROTEOMIC APPROACH

PP 05 IBD (Posters)  et al.

IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON INTERLEUKIN-17A (IL-17A) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

PP 05 IBD (Posters)  et al.

IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY
IMPACT OF OZANIMOD (OZA) ON C-REACTIVE PROTEIN (CRP) LEVELS AND THE ASSOCIATION WITH OZA EFFICACY IN PATIENTS (PTS) WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC): RESULTS FROM THE PHASE 3 TRUE NORTH (TN) STUDY

PP 05 IBD (Posters)  et al.

IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
IMPROVEMENT IN INFLAMMATORY BIOMARKER LEVELS THROUGH WEEK 12 IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PATIENTS TREATED WITH GUSELKUMAB: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

PP 05 IBD (Posters)  et al.

TOFACITINIB RELATED CANCER RISK: RESULTS FROM A SYSTEMATIC REVIEW WITH META-ANALYSIS
TOFACITINIB RELATED CANCER RISK: RESULTS FROM A SYSTEMATIC REVIEW WITH META-ANALYSIS

PP 05 IBD (Posters)  et al.

NEW INSIGHTS INTO THE MECHANISM OF ACTION OF GRANULOCYTE-MONOCYTE APHERESIS REVEALED BY SINGLE-CELL TRANSCRIPTOMIC ANALYSIS
NEW INSIGHTS INTO THE MECHANISM OF ACTION OF GRANULOCYTE-MONOCYTE APHERESIS REVEALED BY SINGLE-CELL TRANSCRIPTOMIC ANALYSIS

PP 05 IBD (Posters)  et al.

ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES
ANALYSIS OF INTESTINAL TISSUE FROM NEWLY DIAGNOSED PATIENTS WITH INFLAMMATORY BOWEL DISEASE REVEALS DISTINCT PROTEOMIC PROFILES

PP 05 IBD (Posters)  et al.

PREVALENCE OF MULTIPLE SCLEROSIS IS NOT HIGHER IN INFLAMMATORY BOWEL DISEASE POPULATION: A CASE CONTROL STUDY
PREVALENCE OF MULTIPLE SCLEROSIS IS NOT HIGHER IN INFLAMMATORY BOWEL DISEASE POPULATION: A CASE CONTROL STUDY

PP 05 IBD (Posters)  et al.

RELATION BETWEEN SERUM INTERLEUKIN 33 CONCENTRATION, DEPRESSIVE SYMPTOMS AND SLEEP QUALITY IN INFLAMMATORY BOWEL DISEASE
RELATION BETWEEN SERUM INTERLEUKIN 33 CONCENTRATION, DEPRESSIVE SYMPTOMS AND SLEEP QUALITY IN INFLAMMATORY BOWEL DISEASE

PP 05 IBD (Posters)  et al.

LONG-TERM OUTCOMES OF ORAL ANTIBIOTICS COMBINATION THERAPY FOR INDUCTION AND MAINTENANCE OF ULCERATIVE COLITIS
LONG-TERM OUTCOMES OF ORAL ANTIBIOTICS COMBINATION THERAPY FOR INDUCTION AND MAINTENANCE OF ULCERATIVE COLITIS

PP 05 IBD (Posters)  et al.

REINITIATION OF OZANIMOD AFTER DOSE INTERRUPTION: ASSESSMENT OF EFFECT ON HEART RATE
REINITIATION OF OZANIMOD AFTER DOSE INTERRUPTION: ASSESSMENT OF EFFECT ON HEART RATE

PP 05 IBD (Posters)  et al.

PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS
PREGNANCY OUTCOMES IN THE OZANIMOD CLINICAL DEVELOPMENT PROGRAM IN ULCERATIVE COLITIS, CROHN’S DISEASE, AND RELAPSING MULTIPLE SCLEROSIS

PP 05 IBD (Posters)  et al.

ANTI-INFLAMMATORY EFFECT OF MAQUI EXTRACT ON PPAR-Α EXPRESSION IN EPITHELIAL AND MACROPHAGE CELLS IN COLON TISSUE FROM EXPERIMENTAL MODEL OF CROHN’S DISEASE
ANTI-INFLAMMATORY EFFECT OF MAQUI EXTRACT ON PPAR-Α EXPRESSION IN EPITHELIAL AND MACROPHAGE CELLS IN COLON TISSUE FROM EXPERIMENTAL MODEL OF CROHN’S DISEASE

PP 05 IBD (Posters)  et al.

EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE
EX VIVO EFFECTS OF INFLIXIMAB ON THE LONG NON-CODING RNAS EXPRESSION LEVELS IN CROHN´S DISEASE

PP 05 IBD (Posters)  et al.

ASSESSING THE EVOLVING NUANCES OF JAK INHIBITOR PRESCRIPTION IN ULCERATIVE COLITIS (UC) PATIENTS
ASSESSING THE EVOLVING NUANCES OF JAK INHIBITOR PRESCRIPTION IN ULCERATIVE COLITIS (UC) PATIENTS

PP 05 IBD (Posters)  et al.

Item 261 - 280 / 826
1 2 3 4 5 6 7 8 9 10 11 12 13
14
15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42